RTP Mobile Logo
RTP TV: Part I — HER2-Positive Breast Cancer
Released June 2012

The first seminar of our online, integrated educational course explores topics relevant to the treatment of HER2-positive breast cancer. Originally held on June 21, 2012, Part I features Drs Kimberly L Blackwell and Mark D Pegram.

CE Disclosures and Faculty Information

  • TARGET AUDIENCE

    This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

    OVERVIEW OF ACTIVITY

    The human epidermal growth factor receptor gene (HER2) is amplified in approximately 20% of breast cancer cases, and its presence marks an aggressive form of the disease, historically associated with significantly shortened disease-free and overall survival. Preclinical evidence confirms that HER2 has a direct role in the pathogenesis of these cancers, thereby reinforcing perturbation of this pathway as an effective therapeutic strategy. As such, there has been significant investment in clinical research intended to both leverage the potential of currently approved anti-HER2 agents as well as to develop new and novel anti-HER2 therapeutics. This program uses a review of recent ASCO papers and other relevant publications, faculty case presentations and Q&A to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies, including referral of appropriate patients to ongoing pivotal clinical trials.

    LEARNING OBJECTIVES

    • Recall the results of pivotal trials introducing effective new breast cancer therapeutics, and identify their effects on existing treatment algorithms for patients with HER2-positive breast cancer.
    • Individualize the selection of evidence-based neoadjuvant and adjuvant trastuzumab regimens for patients with HER2-overexpressing breast cancer.
    • Explain the scientific rationale for dual molecular targeting as a means of enhancing therapeutic efficacy and overcoming acquired resistance to HER2-directed therapy.
    • Evaluate the efficacy and safety of novel anti-HER2-directed therapies for the treatment of metastatic breast cancer.
    • Communicate the availability of ongoing clinical trials evaluating novel anti-HER2 strategies, and counsel appropriately selected patients with breast cancer about study participation.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    This CME activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Kimberly L Blackwell, MD
    Professor of Medicine
    Director, Breast Cancer Program
    Duke Cancer Institute
    Durham, North Carolina

    Advisory Committee: Eisai Inc, Novartis Pharmaceuticals Corporation; Consulting Agreements: Novartis Pharmaceuticals Corporation, Xcenda; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genomic Health Inc, Novartis Pharmaceuticals Corporation.

    Mark D Pegram, MD
    Director, Breast Oncology Program
    Co-Director, Experimental Therapeutics Program
    Professor of Medicine
    Stanford University Medical Center
    Stanford, California

    Advisory Committee: Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Millennium: The Takeda Oncology Company; Consulting Agreement: Genentech BioOncology; Data and Safety Monitoring Board: Pfizer Inc.

    MODERATOR Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genentech BioOncology.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2012
    Expiration date: June 2013

Acknowledge and close

Watch Video
(WiFi is recommended for best performance):